US6524832B1
(en)
|
1994-02-04 |
2003-02-25 |
Arch Development Corporation |
DNA damaging agents in combination with tyrosine kinase inhibitors
|
US5874442A
(en)
*
|
1995-12-22 |
1999-02-23 |
Schering-Plough Corporation |
Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
|
CA2240846C
(en)
*
|
1995-12-22 |
2002-07-16 |
Schering Corporation |
Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
|
DE19624659A1
(de)
|
1996-06-20 |
1998-01-08 |
Klinge Co Chem Pharm Fab |
Neue Pyridylalken- und Pyridylalkinsäureamide
|
US6451816B1
(en)
|
1997-06-20 |
2002-09-17 |
Klinge Pharma Gmbh |
Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
|
US5767274A
(en)
*
|
1996-06-28 |
1998-06-16 |
Biomeasure, Incorporated |
Prenyl transferase inhibitors
|
US5925757A
(en)
*
|
1996-07-26 |
1999-07-20 |
Schering Corporation |
Method for preparing carboxamides
|
US5861395A
(en)
*
|
1996-09-13 |
1999-01-19 |
Schering Corporation |
Compounds useful for inhibition of farnesyl proteins transferase
|
KR20000036120A
(ko)
*
|
1996-09-13 |
2000-06-26 |
둘락 노먼 씨. |
파르네실 단백질 트랜스퍼라제에 대한 트리사이클릭 저해제
|
US6071907A
(en)
*
|
1996-09-13 |
2000-06-06 |
Schering Corporation |
Tricyclic compounds useful as FPT inhibitors
|
US5994364A
(en)
|
1996-09-13 |
1999-11-30 |
Schering Corporation |
Tricyclic antitumor farnesyl protein transferase inhibitors
|
EP0927181A1
(en)
*
|
1996-09-13 |
1999-07-07 |
Schering Corporation |
Tricyclic compounds useful as fpt inhibitors
|
KR20000036111A
(ko)
*
|
1996-09-13 |
2000-06-26 |
둘락 노먼 씨. |
파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
|
US5985879A
(en)
*
|
1996-09-13 |
1999-11-16 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
ATE281450T1
(de)
*
|
1996-09-13 |
2004-11-15 |
Schering Corp |
Verbindungen als inhibitoren von farnesylprotein- transferase
|
US6040305A
(en)
*
|
1996-09-13 |
2000-03-21 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US5945429A
(en)
*
|
1996-09-13 |
1999-08-31 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6030982A
(en)
*
|
1996-09-13 |
2000-02-29 |
Schering Corporationm |
Compounds useful for inhibition of farnesyl protein transferase
|
CA2266014A1
(en)
*
|
1996-09-13 |
1998-03-19 |
Schering Corporation |
Tricyclic compounds useful for inhibition of farnesyl protein transferase
|
US6130229A
(en)
*
|
1996-10-09 |
2000-10-10 |
Schering Corporation |
Tricyclic compounds having activity as RAS-FPT inhibitors
|
US5998620A
(en)
*
|
1997-03-25 |
1999-12-07 |
Schering Corporation |
Synthesis of intermediates useful in preparing tricyclic compounds
|
CA2284646C
(en)
*
|
1997-03-25 |
2004-04-06 |
Schering Corporation |
Synthesis of intermediates useful in preparing tricyclic compounds
|
US6689789B2
(en)
|
1997-06-17 |
2004-02-10 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6218401B1
(en)
|
1997-06-17 |
2001-04-17 |
Schering Corporation |
Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
|
US6211193B1
(en)
|
1997-06-17 |
2001-04-03 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6159984A
(en)
*
|
1997-06-17 |
2000-12-12 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6576639B1
(en)
|
1997-06-17 |
2003-06-10 |
Schering Corporation |
Compounds for the inhibition of farnesyl protein transferase
|
EP0989983B1
(en)
*
|
1997-06-17 |
2004-08-11 |
Schering Corporation |
Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
|
WO1998057949A1
(en)
*
|
1997-06-17 |
1998-12-23 |
Schering Corporation |
Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
|
US6426352B1
(en)
|
1997-06-17 |
2002-07-30 |
Schering Corporation |
Sulfonamide inhibitors of farnesyl-protein transferase
|
ATE227281T1
(de)
*
|
1997-06-17 |
2002-11-15 |
Schering Corp |
Verbindungen als farnesyl-protein transferase inhibitoren
|
AU8253498A
(en)
*
|
1997-06-17 |
1999-01-04 |
Schering Corporation |
Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
|
US6225322B1
(en)
|
1997-06-17 |
2001-05-01 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6239140B1
(en)
|
1997-06-17 |
2001-05-29 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6051582A
(en)
*
|
1997-06-17 |
2000-04-18 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
US6358968B1
(en)
|
1997-06-17 |
2002-03-19 |
Schering Corporation |
N-substituted urea inhibitors of farnesyl-protein transferase
|
HUP0002954A3
(en)
*
|
1997-06-17 |
2002-11-28 |
Schering Corp |
Novel n-substituted urea inhibitors of farnesyl-protein transferase
|
US6228865B1
(en)
|
1997-06-17 |
2001-05-08 |
Schering Corporation |
Compounds useful for inhibition of farnesyl protein transferase
|
DE19756261A1
(de)
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
|
DE19756235A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
|
US6903118B1
(en)
|
1997-12-17 |
2005-06-07 |
Klinge Pharma Gmbh |
Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
|
DE19756212A1
(de)
*
|
1997-12-17 |
1999-07-01 |
Klinge Co Chem Pharm Fab |
Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
|
US6632455B2
(en)
|
1997-12-22 |
2003-10-14 |
Schering Corporation |
Molecular dispersion composition with enhanced bioavailability
|
CA2336448A1
(en)
|
1998-07-02 |
2000-01-13 |
Christopher J. Dinsmore |
Inhibitors of prenyl-protein transferase
|
US6358985B1
(en)
|
1998-07-02 |
2002-03-19 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6307048B1
(en)
|
1998-11-20 |
2001-10-23 |
Schering Corporation |
Enantioselective alkylation of tricyclic compounds
|
CO5150169A1
(es)
*
|
1998-11-20 |
2002-04-29 |
Schering Corp |
Sintesis de intermediarios utiles para pareparar compuestos triciclicos
|
US6372909B1
(en)
|
1998-11-20 |
2002-04-16 |
Schering Corporation |
Synthesis of intermediates useful in preparing tricyclic compounds
|
US6372747B1
(en)
|
1998-12-18 |
2002-04-16 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
US6800636B2
(en)
|
1998-12-18 |
2004-10-05 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
AU776558B2
(en)
*
|
1998-12-18 |
2004-09-16 |
Schering Corporation |
Tricyclic farnesyl protein transferase inhibitors
|
CO5160344A1
(es)
*
|
1998-12-18 |
2002-05-30 |
Schering Corp |
Inhibidores de transferasa de proteina farnesilo
|
US6362188B1
(en)
|
1998-12-18 |
2002-03-26 |
Schering Corporation |
Farnesyl protein transferase inhibitors
|
EP1031564A1
(en)
|
1999-02-26 |
2000-08-30 |
Klinge Pharma GmbH |
Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
|
US6316462B1
(en)
|
1999-04-09 |
2001-11-13 |
Schering Corporation |
Methods of inducing cancer cell death and tumor regression
|
WO2002022579A2
(en)
*
|
2000-09-11 |
2002-03-21 |
Sepracor, Inc. |
Antipsychotic sulfonamide-heterocycles, and methods of use thereof
|
MXPA04001608A
(es)
|
2001-08-21 |
2004-07-08 |
Schering Corp |
Un procedimiento de sintesis de un intermediario de cetona triciclica.
|
CA2463579A1
(en)
|
2001-10-16 |
2003-04-24 |
Hypnion, Inc. |
Treatment of cns disorders using cns target modulators
|
US7189757B2
(en)
|
2001-10-16 |
2007-03-13 |
Hypnion, Inc. |
Treatment of sleep disorders using CNS target modulators
|
US7355042B2
(en)
|
2001-10-16 |
2008-04-08 |
Hypnion, Inc. |
Treatment of CNS disorders using CNS target modulators
|
AU2003299124A1
(en)
|
2002-09-20 |
2004-04-23 |
Laboratoires Serono Sa |
Piperazine derivatives and methods of use
|
AU2002334383A1
(en)
*
|
2002-09-24 |
2004-04-19 |
Morepen Laboratories Limited |
An improved process for the production of desloratadine
|
US7132539B2
(en)
|
2002-10-23 |
2006-11-07 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
WO2005017160A2
(en)
|
2003-08-13 |
2005-02-24 |
Children's Hospital Medical Center |
Mobilization of hematopoietic cells
|
US7411069B2
(en)
|
2003-12-10 |
2008-08-12 |
Hypnion, Inc. |
Doxepin analogs and methods of use thereof
|
US7482460B2
(en)
|
2003-12-10 |
2009-01-27 |
Hypnion, Inc. |
Doxepin analogs and methods of use thereof
|
US7326721B2
(en)
|
2003-12-10 |
2008-02-05 |
Hypnion, Inc. |
Doxepin analogs and methods of use thereof
|
US7524864B2
(en)
|
2004-04-23 |
2009-04-28 |
Hypnion, Inc. |
Methods of treating sleep disorders
|
CA2590979A1
(en)
|
2004-12-13 |
2006-06-22 |
Schering Corporation |
Novel farnesyl protein transferase inhibitors and their use to treat cancer
|
DE102005017116A1
(de)
*
|
2005-04-13 |
2006-10-26 |
Novartis Ag |
Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
ES2498043T3
(es)
*
|
2006-06-06 |
2014-09-24 |
Cornerstone Therapeutics Inc. |
Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas
|
US7943622B2
(en)
|
2006-06-06 |
2011-05-17 |
Cornerstone Therapeutics, Inc. |
Piperazines, pharmaceutical compositions and methods of use thereof
|
SG172685A1
(en)
|
2006-06-28 |
2011-07-28 |
Amgen Inc |
Glycine transporter-1 inhibitors
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
CN101679266B
(zh)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
Pim激酶抑制剂及其应用方法
|
US8093237B2
(en)
*
|
2007-03-15 |
2012-01-10 |
Aryx Therapeutics, Inc. |
Dibenzo[b,f][1,4]oxazapine compounds
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
JP5099731B1
(ja)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
p53活性を増大する置換ピペリジン及びその使用
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
JP2013522292A
(ja)
|
2010-03-16 |
2013-06-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
インダゾール化合物およびそれらの使用
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
DK2606134T3
(da)
|
2010-08-17 |
2019-07-22 |
Sirna Therapeutics Inc |
RNA-Interferens-formidlet inhibering af hepatitis-B-virus (HBV)-genekspression ved hjælp af kort interfererende nukleinsyre (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3609922A2
(en)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|